LATEST PRESS RELEASES

201 views6 min read

Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Cybin
-- First-in-human Phase 1/2a trial evaluating the proprietary deuterated psilocybin analog CYB003 expected to begin in mid-2022 --TORONTO, June 09, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today announced... Read More...
940 views4 min read

Optimi Health Finalizes Partnership and Psilocybin Supply Agreement With ATMA Journey Centers

Optimi Health
Optimi Health Corp.Strategic partnership will focus on improving regulatory outcomes in therapist training and safe supply of psilocybinVANCOUVER, British Columbia, June 08, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessib... Read More...
CalendarM & A930 views4 min read

Numinus announces shareholder approval of resolution in connection with the proposed acquisition of Novamind

Numinus Wellness
Novamind shareholders, at a separate meeting held today, have also approved the transaction Transaction expected to be completed on or about June 10, 2022 VANCOUVER, BC, June 8, 2022 - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce shareholders have approved the Company's resolution to... Read More...
M & A866 views8 min read

Cybin Acquires DMT Clinical Study from Entheon Biomedical

Cybin
-- Acquisition of largest Phase 1 DMT study conducted to date is expected to accelerate CYB004 program timeline by nine months ---- Phase 1 study evaluating pharmacokinetics/pharmacodynamics of DMT currently underway and will inform clinical path forward --TORONTO, June 07, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN)... Read More...
1117 views3 min read

Lobe Sciences Announces Share Consolidation

Lobe Sciences
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announces that its board of directors has authorized the implementation of a consolidation (the "Consolidation") of the Company's common shares (the "Shares") on the basis of one (1) post-Consolidation Sha... Read More...
977 views7 min read

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First Stability Test Under a Health Canada Approved cGMP Laboratory

Red Light Holland
Red Light Holland's iMicrodose packs containing Psilocybe Tampanensis Truffles, produced in the Netherlands, tested at CCrest Laboratories, under a Health Canada approved Psilocybin license.Red Light Holland and CCrest Laboratories continue to demonstrate their strong commitment to the highest standards for naturally occurring Psilocybin ... Read More...
38 views3 min read

Novamind Announces New Patient Financing Options

Novamind
TORONTO, ON / ACCESSWIRE / June 2, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, today announced new patient financing options to help patients access critical mental healthcare services at its six clinic locations in Utah. The Company now accepts Syn... Read More...
79 views7 min read

Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy

Cybin
TORONTO, June 02, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", is pleased to announce the publication of a peer-reviewed article introducing EMBARK, a model of psychedelic-assisted psychotherapy that integra... Read More...
137 views7 min read

Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder

Cybin
-- CYB003 is the first psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder --TORONTO, May 31, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", is pleased to an... Read More...
1174 views5 min read

Open For Business: Optimi Completes First Grow of Psilocybin Mushrooms and Introduces Head of Cultivation

Optimi Health
VANCOUVER, British Columbia, May 25, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce an historical milestone in the Company’s road to ... Read More...
36 views6 min read

Red Light Holland CCO Russell Peters Completes Psilocybin Truffles Journey in Amsterdam and Will Live Stream a Q&A Today (May 24th, 2022) at 2pm ET on Twitter @TheRealRussellP (3.9m Followers) and Multiple Red Light Social Media Accounts

Red Light Holland
CEO Todd Shapiro will interview Russell Peters later today, May 24th, at 8 PM CET / 2PM ET in front of an invite only audience about Russell's candid journey with Red Light's Therapist Jeff HamburgThis unique candid Red Light Event will be live streamed on Russell Peters' Twitter account (@TheRealRussellP - 3.9m) plus Todd Shapiro's and R... Read More...
130 views1 min read

Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson’s Disease in Psilocybin Study

Silo Pharma
Study is examining effects of Psilocybin on Inflammatory MarkersENGLEWOOD CLIFFS, N.J., May 19, 2022 --  Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announces that it in conjunction with the University of California San Francisco (UCSF), researc... Read More...
1401 views3 min read

Delic Corp to Present on Company’s Expansion Strategy, Industry Outlook at H.C. Wainwright Conference

Delic Holdings
Matt Stang, Co-founder and CEO of Delic Corp, will share the Company's strategic targets for the remainder of the year at the H.C. Wainwright Annual Global Life Sciences Conference from May 23-26 VANCOUVER, BC, May 18, 2022 - Delic Holdings Corp ("Delic") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for ... Read More...
Financials1059 views5 min read

Mydecine Announces First Quarter 2022 Financial Results and Highlights

Mydecine Innovations Group
DENVER, May 16, 2022 -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results and provided a business update for the first quarter of 2022.  “Our team had an ext... Read More...
46 views8 min read

Red Light Holland Successfully Imports 200 Psilocybin iMicrodose Packs, Sold in The Netherlands, Into Canada Under a Third Health Canada Approved Psilocybin Import Permit To cGMP Laboratory

Red Light Holland
Red Light Holland proudly exports a commercial sale of 3000 Grams (200 x 15g packs) of Psilocybin Truffles (Psilocybe Tampanensis) grown in the Company's Farm in Horst, The Netherlands to its laboratory partner, CCrest Laboratories Inc., a cGMP pharmaceutical laboratory in Montreal, CanadaRed Light Holland has an established alliance with... Read More...
917 views5 min read

Delic Holdings Corp Provides Default Status Update

Delic Holdings
VANCOUVER, BC, May 16, 2022 - Delic Holdings Corp ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Management Cease Trade Orders ("... Read More...
893 views4 min read

Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment

Numinus Wellness
Approval Marks Numinus' First use of Psilocybin-Assisted Therapy Treatment Outside of Clinical Trials VANCOUVER, BC, May 16, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Health Ca... Read More...
Joint Venture702 views4 min read

Ketamine Wellness Centers Announces Partnership With The Veterans Administration (VA) in Arizona

Delic Holdings
Nation's Largest Ketamine Therapy Provider to Cover Out-Of-Pocket Costs for Veterans Experiencing Treatment-resistant Depression, PTSD and Anxiety GILBERT, Ariz., May 12, 2022 - Ketamine Wellness Centers (KWC), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings Corp ("Delic") (CSE: DELC) (OTCQB: DELCF) (... Read More...
Calendar217 views6 min read

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

Bright Minds Biosciences
-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on May 19, 2022, 4:00pm ET -- VANCOUVER, British Columbia, May 12, 2022 --  Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment o... Read More...
474 views5 min read

Red Light Holland Engages Akwasi Owusu-Bempah, Respected Academic, Author and Drug Law Reform and Drug Equity Expert, as Advisor to Advisory Board

Red Light Holland
Toronto, Ontario--(Newsfile Corp. - May 11, 2022) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) ("Red Light Holland"), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands is pleased to announce it has enga... Read More...
Calendar116 views7 min read

Novamind Files Management Information Circular for Special Meeting of Shareholders and Announces Receipt of Interim Court Order for Plan of Arrangement

Novamind
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.Shareholders are encouraged to vote their common shares prior to the proxy deadline of June 6, 2022 at 2:00 p.m. ETTORONTO, ON / ACCESSWIRE / May 11, 2022 ... Read More...
115 views3 min read

Numinus to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022

Numinus Wellness
VANCOUVER, BC, May 11, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a fireside chat hosted by Patrick Trucchio, H.... Read More...
Calendar116 views7 min read

Numinus Mails Materials for Special Meeting of Shareholders and Announces Interim Court Order for Plan of Arrangement

Numinus Wellness
Shareholders are encouraged to vote their common shares prior to the proxy deadline of June 6, 2022 at 11:00 a.m. PT VANCOUVER, BC, May 10, 2022 - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) today announces the mailing of its management information circular (the "Circular") and related materials for the spe... Read More...
Calendar122 views8 min read

Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain

Cybin
- Preliminary data confirm Flow's ability to successfully measure neuro-effect of ketamine over 10 days -- Results to be presented at PSYCH Symposium taking place in London on May 11, 2022 -LOS ANGELES & TORONTO, May 09, 2022--(BUSINESS WIRE)--Kernel, a leader in non-invasive neuroimaging, and Cybin Inc. (NEO:CYBN) (NYSE American:CYBN... Read More...
118 views5 min read

Optimi Health Applauds Health Canada’s Position on Drug Quality and Goods and Manufacturing Practices (GMP) for Psilocybin

Optimi Health
VANCOUVER, British Columbia, May 09, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) CEO, Bill Ciprick, issued a statement today in response to Health Canada’s May 6 Notice to Stakeholders “regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the... Read More...
CalendarFinancials41 views3 min read

COMPASS Pathways plc to announce first quarter 2022 financial results on 10 May 2022

COMPASS Pathways plc
COMPASS PathwaysLONDON, May 03, 2022 -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2022, and provide an update on recent business developments on 10 May... Read More...
Financials57 views4 min read

Delic Holdings Corp Announces Late Filing Of Annual Financial Statements, Md&a And Management Cease Trade Order

Delic Holdings
VANCOUVER, BC, May 3, 2022 - Delic Holdings Corp ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announces that as a result of delays to its audit, the Company's annual financial statements and accompanying management's discussion and analysis for the fiscal ye... Read More...
116 views7 min read

Allied Corp Announces Approval of Psychoactive (THC) Quota for the Production of Colombian THC Cannabis Flower

Allied
KELOWNA, British Columbia, May 03, 2022 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce the approval of its 2022 quota for the production and sale of THC cannabis flower. On April 29th, 2022 the Colombian government approved Allied’s application for its THC cannabis flower quota for the 2022 calendar year.... Read More...
940 views4 min read

Novamind Announces Virtual Group Health Coaching

Novamind
Collaboration with HealCommunity Offers Remote Access to Reimbursable Group Therapy OptionTORONTO, ON / ACCESSWIRE / May 2, 2022 / Novamind Inc.(CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its collaboration with virtual health coaching experts, Hea... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!